SSR181507, A Dopamine D2 Receptor Antagonist and 5-HT 1A Receptor Agonist. I: Neurochemical and Electrophysiological Profile

Neuropsychopharmacology

Volumn 28, Issue 12, 2003, Pages 2064-2076

  Claustre, Yves ^a   De Peretti, Danielle ^a   Brun, Philippe ^b   Gueudet, Christiane ^a   Allouard, Nathalie ^a   Alonso, Richard ^a   Lourdelet, Joëlle ^a   Oblin, André ^a   Damoiseau, Gabrielle ^a   Françon, Dominique ^a   Suaud Chagny, Marie Françoise ^b   Steinberg, Régis ^a   Sevrin, Mireille ^a   Schoemaker, Hans ^a   George, Pascal ^a   Soubrié, Philippe ^a   Scatton, Bernard ^a  

^a SANOFI   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

5 HT1A agonist; Atypical antipsychotic; D2 antagonist; Mesocorticolimbic selectivity

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 8 BENZOYL N (7 CHLORO 2,3 DIHYDRO 1,4 BENZODIOXIN 1 YL) 8 AZABICYCLO[3.2.1]OCTANE 3 METHANAMINE; AMISULPRIDE; APOMORPHINE; BENZODIOXAN DERIVATIVE; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; ELIPRODIL; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HALOPERIDOL; METHYLAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OLANZAPINE; PARGYLINE; PAROXETINE; PROTEIN FOS; RACLOPRIDE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SSR 181507; TROPANE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVITY; CELL COUNT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DORSAL RAPHE NUCLEUS; DRUG ACTIVITY; DRUG EXPOSURE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ELECTROCHEMISTRY; ELECTROPHYSIOLOGY; HUMAN; HUMAN CELL; IC 50; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LIMBIC SYSTEM; MALE; MICRODIALYSIS; NEUROCHEMISTRY; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

EID: 10744226198     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300262     Document Type: Article

References (67)

1. 2 function. Neuroscience 91: 607-620.
2. Arborelius LE, Nomikos GG, Hacksell U, Svenson TH (1993). (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand 148: 465-466.
3. 1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol 15: 37-46.
4. 2C receptors. Br J Pharmacol 115: 622-628.
5. Borison RL, Albrecht JW, Diamond BL (1990). Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacol Bull 26: 207-210.
6. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F (1995). Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: 68-72.
7. 3H- spiroperidol on rat striatal membranes. Eur J Pharmacol 50: 283-284.
8. Brun P, Steinberg R, Le Fur G, Soubrié P (1995). Blockade of neurotensin receptor by SR 48692 potentiates the facilitatory effect of haloperidol on the evoked in vivo dopamine release in the rat nucleus accumbens. J Neurochem 64: 2073-2079.
9. Buckley NJ, Bonner TI, Buckley CM, Brann MR (1989). Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 35: 469-476.
10. Burnet PWJ, Eastwood SL, Harrison PJ (1996). 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15: 442-455.
11. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
12. Dearry A, Gringrich JA, Falardeau P, Fremeau RT, Bates MD, Caron MG (1990). Molecular cloning and expression of the gene for a human D1 dopamine receptor. Nature 347: 72-76.
13. 1A receptor agonist. II. Behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology, 2003.
14. 3 receptors: use of the knock-out mice approach. In: Di Chiara G (ed) Dopamine in the CNS II. Springer: Heidelberg. pp 239-264.
15. Deutch AY, Lee MC, Iadarola MJ (1992). Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 3: 332-341.
16. Furchgott RF (1972). The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H, Muscholl E (eds) Handbook of Experimental Pharmacology Vol. XXXIII Springer: Berlin, Heidelberg, New York. pp 283-335.
17. Goff D, Midha K, Brotman A, McCormick S, Waites M, Amico E (1991). An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11: 193-197.
18. Grace AA, Bunney BS (1983). Intracellular and extracellular electrophysiology of nigral dopaminergic neurons 1. Identification and characterization. Neuroscience 10: 301-315.
19. Grandy DK, Marchionni MA, Makam H, Stofko RE, Alfano M, Frothingham L et al (1989). Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc Natl Acad Sci USA 86: 9762-9766.
20. Greengrass P, Bremner R (1979). Binding characteristics of 3H-prazosin to rat brain alpha-adrenergic receptors. Eur J Pharmacol 55: 323-326.
21. Haigler HJ, Aghajanian GK (1974). Lysergic acid diethylamide and serotonin: a comparison of effects on serotonergic neurons and neurons receiving a serotonergic inputs. J Pharmacol Exp Ther 188: 688-699.
22. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY (2001). 5-HT2A and D2 receptor blockade increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76: 1521-1531.
23. Jones-Humble SA, Durcan MJ, Lyerly D, Norton RM, Tang FLM, Russell AV et al (1996). Preclinical neurochemical and electrophysiological profile of 1192U90 a potential antipsychotic. Neuropsychopharmacology 15: 217-230.
24. 1A receptor. Eur J Pharmacol 441: 137-140.
25. Kapur S, Remington G (1996). Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466-476.
26. Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Kufferle B et al (2002). Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder implication for psychopharmacology. World J Biol Psychiatry 3: 133-146.
27. Kenny BA, Chalmers DH, Philpott PC, Naylor AM (1995). Characterization of an alpha 1D-adrenoceptor mediating the contractile response of rat aorta to noradrenaline. Br J Pharmacol 115: 981-986.
28. Köhler C, Hall H, Ogren SO, Gawell L (1985). Specific in vitro and in vivo binding of 3H-raclopride, a potent substituted benzamide drug with high affinity for dopamine D-2 receptors in the rat brain. Biochem Pharmacol 34: 2251-2259.
29. Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J (1993). Depression in first-episode schizophrenia. Am J Psychiatry 150: 1643-1648.
30. Kuroki T, Meltzer HY, Ichikawa J (1999). Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288: 774-781.
31. Liberman RP, Corrigan PW (1992). Is schizophrenia a neurological disorder? J Neuropsychiatry Clin Neurosci 4: 119-124.
32. Martin GR, Humphrey PA (1994). Receptors for 5-hydroxytryptamine: current perspectives on classification and nomenclature. Neuropharmacology 33: 261-273.
33. Meltzer HY (1999). The role of serotonin in antipsychotic drug action. Neuropharmacology 21: 1065-1155.
34. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255.
35. Millan MJ (2000). Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors. J Pharmacol Exp Ther 295: 853-861.
36. 1A receptors: respective distributions of encoding mRNA, receptor protein and binding sites by in situ hybridization histochemistry, radioimmunohistochemistry and autoradiographic mapping in the rat brain. Neurochem Int 19: 453-465.
37. Miyamoto S, Duncan G, Mailman R, Lieberman J (2000). Developing novel antipsychotic drugs: strategies and goals. Curr Opin CPNS Invest Drugs 2: 25-39.
38. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR (1993). Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 43: 320-327.
39. 32S]thio)-triphosphate binding and antibody study. Mol Pharmacol 55: 564-574.
40. 1A receptors. Eur J Pharmacol 355: 245-256.
41. Nomikos GG, Iurlo M, Andersson JL, Kimura K, Svensson TH (1994). Systemic administration of amperozide, a new atypical antipsychotic drug, preferentially increases dopamine release in the rat medial prefrontal cortex. Psychopharmacology 115: 147-156.
42. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: Sydney, Australia.
43. Richelson E, Souder T (2000). Binding of antipsychotic drugs to human brain receptors. Focus on newer generation compounds. Life Sci 68: 29-39.
44. Robertson GS, Fibiger HC (1992). Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46: 315-328.
45. Robinson DS, Alms DR, Shrotriya RC, Messina M, Wickramarante P (1989). Serotonergic anxiolytics and treatment of depression. Psychopathology 22: 27-36.
46. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48: 229-237.
47. Sakaue M, Somboonthum P, Nishihara B, Koyama Y, Hashimoto H, Baba A et al (2000). Postsynaptic 5-hydroxytryptamine (1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex. Br J Pharmacol 129: 1028-1034.
48. 1A receptors. Psychopharmacology 108: 85-92.
49. Scatton B, Sanger DJ (2000). Pharmacological and molecular targets in the search for novel antipsychotics. Behav Pharmacol 11: 242-256.
50. 3 receptors and σ sites in the bovine caudate nucleus. Eur J Pharmacol 242: R1-R2.
51. 3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 280: 83-97.
52. 3H]8-OH-DPAT labels the serotonin transporter in the rat striatum. Eur J Pharmacol 124: 371-373.
53. Semba J, Sakai M, Miyoshi R, Mataga N, Fukamauch F, Kito S (1996). Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, n. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study. Neurochem Int 29: 435-442.
54. Shen Y, Monsma FJ, Metcalf MA, Jose PA, Hamblin MW, Sibley D (1993). Molecular cloning and expression of 5-hydroxytryptamine7 serotonin receptor subtype. J Biol Chem 268: 18200-18204.
55. Sibley DR, Monsma FJ (1992). Molecular biology of dopamine receptors. Trends Pharmacol Sci 13: 61-69.
56. 1A receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry 39: 919-928.
57. Skarsfeldt T (1995). Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 281: 289-294.
58. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC (1990). Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 247: 146-151.
59. Suaud-Chagny MF, Brun P, Buda M, Gonon F (1992). Fast in vivo monitoring of electrically evoked dopamine release by differential pulse amperometry with untreated carbon fibre electrodes. J Neurosci Methods 45: 183-190.
60. Sumiyoshi T, Matsui M, Nohara S, Yamashita I, Kurachi M, Sumiyoshi C et al (2001). Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158: 1722-1725.
61. Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Uehara T, Kurachi M et al (2000). Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia. J Clin Psychopharmacol 20: 386-388.
62. Tremblay PO, Gervais J, Rouillard C (1998). Modification of haloperidol-induced pattern of c-fos expression by serotonin agonists. Eur J Neurosci 10: 3546-3555.
63. Van Tol HHM, Bunzow JR, Guan HG, Sunahara RK, Seeman P, Niznik HB et al (1991). Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 350: 610-614.
64. Volonté M, Monferini E, Cerutti M, Fodritto F, Borsini F (1997). BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J Neurochem 59: 182-190.
65. Wadenberg ML, Ahlenius S (1991). Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J Neural Transm [Gen Sect] 83: 43-53.
66. Weinberger DR, Lipska BK (1995). Cortical maldevelopment, antipsychotic drugs and schizophrenia: a search for common ground. Schizophr Rev 16: 87-110.
67. White FJ, Wang RY (1983). Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221: 1054-1057.